Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Sees Large Decline in Short Interest

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a significant drop in short interest in August. As of August 31st, there was short interest totaling 43,251 shares, a drop of 34.5% from the August 15th total of 66,082 shares. Based on an average daily trading volume, of 23,843 shares, the days-to-cover ratio is currently 1.8 days. Currently, 3.3% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Aspire Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Aspire Biopharma Stock Performance

Aspire Biopharma stock opened at $8.58 on Thursday. The firm has a market cap of $12.01 million, a price-to-earnings ratio of -0.12 and a beta of 0.17. Aspire Biopharma has a 1 year low of $3.31 and a 1 year high of $562.92. The firm’s 50 day moving average price is $7.63 and its two-hundred day moving average price is $12.73.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.